Page 263 of 439: studies 2,621 to 2,630 of 4,389, newest first. Back to the psilocybin overview
Fieldwork in Religion March 31, 2020 Anna Lutkajtis 20 citations
Mushrooms containing psilocybin have been used in Indigenous healing ceremonies in Mesoamerica since at least the sixteenth century. However, the sacramental use of mushrooms was only discovered by Westerners in the early to mid-twentieth century. Most notably, the meeting between amateur mycologist Robert Gordon Wasson and Mazatec curandera María Sabina in 1955 resulted in the widespread...
Psychiatric News March 20, 2020 Katie O’connor
Though the field is young, psychedelics appear to hold promise as a treatment for addiction, even as barriers to research persist. Researchers around the world are investigating how drugs such as LSD, MDMA (also known as ecstasy), ketamine, and psilocybin (the active ingredient in magic mushrooms) can treat patients with substance use disorders (SUD). Though there is still a lot to learn, early...
Drug Testing and Analysis March 16, 2020 Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal et al. 38 citations
Abstract Lysergic acid diethylamide (LSD) is a prototypical serotonergic psychedelic drug and the subject of many clinical investigations. In recent years, a range of lysergamides has emerged with the production of some being inspired by the existing scientific literature. Others, for example various 1‐acyl substituted lysergamides, did not exist before their appearance as research chemicals....
Journal of Psychedelic Studies March 12, 2020 Brianna R. Altman, Maha N. Mian, Mitch Earleywine 4 citations
Abstract Objective Given the growing popularity of ayahuasca and other hallucinogens, we sought to identify related expectancies and their role in why people might use this psychoactive brew rather than classic hallucinogens like LSD or psilocybin. Method Experienced users (N = 139) completed an online survey about their use of hallucinogens (including ayahuasca), how their ayahuasca...
Molecules March 5, 2020 J Benko, Stanislava Vranková 18 citations
Increasing prevalence and burden of major depressive disorder presents an unavoidable problem for psychiatry. Existing antidepressants exert their effect only after several weeks of continuous treatment. In addition, their serious side effects and ineffectiveness in one-third of patients call for urgent action. Recent advances have given rise to the concept of psychoplastogens. These compounds...
ACS Chemical Neuroscience March 5, 2020 Meghan Hibicke, Alexus N. Landry, Hannah M. Kramer et al. 211 citations
Psilocybin shows efficacy to alleviate depression in human clinical trials for six or more months after only one or two treatments. Another hallucinogenic drug, esketamine, has recently been U.S. Food and Drug Administration (FDA)-approved as a rapid-acting antidepressant. The mechanistic basis for the antidepressant effects of psilocybin and ketamine appear to be conserved. The efficacy of...
March 1, 2020 Adam Winstock, James W. Rucker 29 citations
Abstract Psychedelics and hallucinogens represent some of the most commonly used drugs in the world, with a history of use steeped in spirituality, counter-culture, and more recently latent therapeutic potential. Sharing a common mechanism of action at the 5-HT2a receptor, drugs such as lysergic acid diethylamide (LSD) and psilocybin, while they can rarely induce significant short-term...
Journal of Psychopharmacology February 28, 2020 Daniel Rosenbaum, Cory R. Weissman, Thomas Anderson et al. 75 citations
Rationale: Microdosing psychedelics – the practice of consuming small, sub-hallucinogenic doses of substances such as LSD or psilocybin – is gaining attention in popular media but remains poorly characterized. Contemporary studies of psychedelic microdosing have yet to report the basic psychiatric descriptors of psychedelic microdosers. Objectives: To examine the practices and demographics of a...
Frontiers in Neuroscience February 4, 2020 Claire J. Foldi, Paul Liknaitzky, M.l. Williams et al. 52 citations
Anorexia nervosa (AN) has the highest mortality rate of any psychiatric disease, yet available pharmacological treatments are largely ineffective due, in part, to an inadequate understanding of the neurobiological drivers that underpin the condition. The recent resurgence of research into the clinical applications of psychedelic medicine for a range of mental disorders has highlighted the...
Journal of the Neurological Sciences January 31, 2020 Tingying Chi, Jessica A. Gold 95 citations
Though there was initial interest in the use of psychedelic drugs for psychiatric treatment, bad outcomes and subsequent passage of the Substance Act of 1970, which placed psychedelic drugs in the Schedule I category, significantly limited potential progress. More recently, however, there has been renewal in interest and promise of psychedelic research. The purpose of this review is to...